Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.
PLoS One. 2012;7(4):e35065. doi: 10.1371/journal.pone.0035065. Epub 2012 Apr 6.
Lysine specific demethylase 1 (LSD1) has been identified and biochemically characterized in epigenetics, but the pathological roles of its dysfunction in lung cancer remain to be elucidated. The aim of this study was to evaluate the prognostic significance of LSD1 expression in patients with non-small cell lung cancer (NSCLC) and to define its exact role in lung cancer proliferation, migration and invasion.
The protein levels of LSD1 in surgically resected samples from NSCLC patients were detected by immunohistochemistry or Western blotting. The mRNA levels of LSD1 were detected by qRT-PCR. The correlation of LSD1 expression with clinical characteristics and prognosis was determined by statistical analysis. Cell proliferation rate was assessed by MTS assay and immunofluorescence. Cell migration and invasion were detected by scratch test, matrigel assay and transwell invasion assay.
LSD1 expression was higher in lung cancer tissue more than in normal lung tissue. Our results showed that over-expression of LSD1 protein were associated with shorter overall survival of NSCLC patients. LSD1 was localized mainly to the cancer cell nucleus. Interruption of LSD1 using siRNA or a chemical inhibitor, pargyline, suppressed proliferation, migration and invasion of A549, H460 and 293T cells. Meanwhile, over-expression of LSD1 enhanced cell growth. Finally, LSD1 was shown to regulate epithelial-to-mesenchymal transition in lung cancer cells.
Over-expression of LSD1 was associated with poor prognosis in NSCLC, and promoted tumor cell proliferation, migration and invasion. These results suggest that LSD1 is a tumor-promoting factor with promising therapeutic potential for NSCLC.
赖氨酸特异性去甲基化酶 1(LSD1)已在表观遗传学中被鉴定和生化表征,但 LSD1 功能障碍在肺癌中的病理作用仍有待阐明。本研究旨在评估 LSD1 表达在非小细胞肺癌(NSCLC)患者中的预后意义,并确定其在肺癌增殖、迁移和侵袭中的确切作用。
通过免疫组织化学或 Western blot 检测手术切除的 NSCLC 患者样本中 LSD1 的蛋白水平。通过 qRT-PCR 检测 LSD1 的 mRNA 水平。通过统计分析确定 LSD1 表达与临床特征和预后的相关性。通过 MTS 测定和免疫荧光法评估细胞增殖率。通过划痕试验、基质胶测定和 Transwell 侵袭试验检测细胞迁移和侵袭。
LSD1 在肺癌组织中的表达高于正常肺组织。我们的结果表明,LSD1 蛋白的过表达与 NSCLC 患者的总生存期缩短相关。LSD1 主要定位于癌细胞核内。使用 siRNA 或化学抑制剂(苯佐卡因)中断 LSD1 的表达抑制了 A549、H460 和 293T 细胞的增殖、迁移和侵袭。同时,LSD1 的过表达增强了细胞生长。最后,LSD1 被证明调节了肺癌细胞中的上皮-间充质转化。
LSD1 的过表达与 NSCLC 的不良预后相关,并促进肿瘤细胞的增殖、迁移和侵袭。这些结果表明,LSD1 是一种具有潜在治疗 NSCLC 潜力的促肿瘤因子。